Abstract
Acquired factor VIII (FVIII) inhibitors are rare, typically occurring in the postpartum period or in the elderly. Their occurrence in childhood is distinctly unusual. Acquired FVIII inhibitors are often life-threatening and refractory to treatment with high doses of human FVIII concentrate. Alternative strategies for control of haemostasis include the use of products with FVIII "bypassing" activity or porcine FVIII (pFVIII) concentrate if the pFVIII titre is sufficiently low (<10-20 porcine Bethesda Units). Corticosteroids and other immunosuppressive therapies are inconsistently effective in eliminating FVIII inhibitors. Accordingly, acquired FVIII inhibitors often require long-term haemostatic management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Haemophilia : the official journal of the World Federation of Hemophilia
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.